Efficacy of Selpercatinib in

Authors

• Lori J Wirth
• Eric Sherman
• Bruce Robinson
• Benjamin Solomon
• Hyunseok Kang
• Jochen Lorch
• Francis Worden
• Marcia Brose
• Jyoti Patel
• Sophie Leboulleux
• Yann Godbert
• Fabrice Barlesi
• John C Morris
• Taofeek K Owonikoko
• Daniel S W Tan
• Oliver Gautschi
• Jared Weiss
• Christelle de la Fouchardière
• Mark E Burkard
• Janessa Laskin
• Matthew H Taylor
• Matthias Kroiss
• Jacques Medioni
• Jonathan W Goldman
• Todd M Bauer
• Benjamin Levy
• Viola W Zhu
• Nehal Lakhani
• Victor Moreno
• Kevin Ebata
• Michele Nguyen
• Dana Heirich
• Edward Y Zhu
• Xin Huang
• Luxi Yang
• Jennifer Kherani
• S Michael Rothenberg
• Alexander Drilon
• Vivek Subbiah
• Manisha H Shah
• Maria E Cabanillas

Publication/Presentation Date

8-27-2020

Abstract

BACKGROUND:

METHODS: We enrolled patients with

RESULTS: In the first 55 consecutively enrolled patients with

CONCLUSIONS: In this phase 1-2 trial, selpercatinib showed durable efficacy with mainly low-grade toxic effects in patients with medullary thyroid cancer with and without previous vandetanib or cabozantinib treatment. (Funded by Loxo Oncology and others; LIBRETTO-001 ClinicalTrials.gov number, NCT03157128.).

Volume

383

Issue

9

First Page

825

Last Page

835

ISSN

1533-4406

Published In/Presented At

Wirth, L. J., Sherman, E., Robinson, B., Solomon, B., Kang, H., Lorch, J., Worden, F., Brose, M., Patel, J., Leboulleux, S., Godbert, Y., Barlesi, F., Morris, J. C., Owonikoko, T. K., Tan, D. S. W., Gautschi, O., Weiss, J., de la Fouchardière, C., Burkard, M. E., Laskin, J., … Cabanillas, M. E. (2020). Efficacy of Selpercatinib in RET-Altered Thyroid Cancers. The New England journal of medicine, 383(9), 825–835. https://doi.org/10.1056/NEJMoa2005651

Disciplines

Medicine and Health Sciences

PubMedID

32846061

Department(s)

Hematology-Medical Oncology Division

Document Type

Article